Sun Yat-sen University Cancer Center
Guangzhou, China
Speakers
1 interview

Li Zhang MD; ESMO 2026: Bi-Specific Antibody-Drug Conjugate Doubles Progression Free Survival in Patients with NSCLC Progressing After Anti-EGFR TKI Therapy
MADRID, Spain—Patients with EGFR-mutated advanced non-squamous non-small cell lung cancer progressing on third-generation EGFR tyrosine kinase inhibitors lived twice as long without progression when…
16 November 2026
8 min